The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab
Frontiers in Immunology · 2023
DOI: 10.3389/fimmu.2023.1292941 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, 2023. Verfasst von Jason E Hawkes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Integrative Skin Science and Research and Pacific Skin Institute, Sacramento, CA, United States. Hauptthemen laut MEDLINE: Psoriasis, Skin Diseases, Vesiculobullous. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disorder characterized by recurrent flares associated with skin erythema, desquamation, and widespread superficial sterile pustules, which may be severe (“lakes of pus”). Systemic symptoms are often present, including malaise, fever, and skin pain. In GPP, innate immune responses are driven by abnormal activation of the interleukin (IL)-36-chemokine-neutrophil axis and excessive neutrophil infiltration. This review highlights the IL-36 pathway in the context of the IL-1 superfamily and describes how unopposed IL-36 signaling can lead to the development of GPP. Targeted inhibition of the IL-36 receptor (IL-36R) is an attractive therapeutic strategy in the treatment of GPP, including flare prevention and sustained disease control. Spesolimab is a first-in-class, humanized, monoclonal antibody that binds specifically to the IL-36R and antagonizes IL-36 signaling. Spesolimab was approved by the US Food and Drug Administration in September 2022 to treat GPP flares in adults and was subsequently approved for GPP flare treatment in other countries across the world. Anti-IL-36R therapy, such as spesolimab, can mitigate flares and address flare prevention in GPP, presumably through rebalancing IL-36 signaling and modulating the pro-inflammatory response of the downstream effectors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Integrative Skin Science and Research and Pacific Skin Institute, Sacramento, CA, United States.
- Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.
- Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, United States.
Zitieren
APA
Hawkes, J. E., Visvanathan, S., & Krueger, J. G. (2023). The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1292941
Vancouver
Hawkes JE, Visvanathan S, Krueger JG. The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab. Frontiers in Immunology. 2023. doi:10.3389/fimmu.2023.1292941
BibTeX
@article{Hawkes2023,
author = {Hawkes, Jason E and Visvanathan, Sudha and Krueger, James G},
title = {The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab},
journal = {Frontiers in Immunology},
year = {2023},
doi = {10.3389/fimmu.2023.1292941}
}
EUVIMED